initial public offerings (IPOs) trading on American exchanges

Tuesday, August 28, 2018

Tilray (TLRY) reported earnings on Tue 28 August 2018 (a/h)

** charts before earnings ** 


** charts after earnings **


  • 2 weeks later

Tilray reports Q2 (Jun) results 
  • Reports Q2 (Jun) GAAP loss of $0.17 per share ($2.4M), including $5.6M in stock compensatinn charges, may not be comparable to the single analyst estimate of ($0.09); revenues rose 94.0% year/year to $9.7 mln vs the $9.01 mln S&P Capital IQ Consensus, driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year. Average net selling price per gram increased from $6.20 to $6.38 YoY. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues.

No comments:

Post a Comment